Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
Establishment Labs Holdings Inc. develops and markets medical technology for women’s health, principally breast aesthetics and reconstruction. The company’s recurring news covers Motiva implants and related minimally invasive platform activity, global product adoption, U.S. and outside-the-U.S. commercialization, and sales channels serving distributors, physicians, hospitals, and clinics.
Updates also include quarterly and annual financial results, revenue guidance, operating expense leverage, adjusted EBITDA commentary, credit-facility refinancing, leadership changes, and health care conference participation. Product and market updates commonly center on the Motiva portfolio, silicone-filled breast and body-shaping implants, and expansion across Europe, Latin America, Asia-Pacific/Middle East, and other markets.
Establishment Labs (NASDAQ: ESTA) reported Q1 2026 revenue of $59.9 million, up 44.7% year-over-year, and raised full-year revenue guidance to $266.5–$268.5 million. Motiva U.S. sales were $19.6 million. Gross margin improved to 70.7% and adjusted EBITDA was $1.2 million. Cash totaled $68.1 million as of March 31, 2026.
The company increased 2026 minimally invasive guidance to exceed $35 million, expects positive adjusted EBITDA every quarter, and aims for free cash flow positivity in H2 2026.
Establishment Labs (NASDAQ: ESTA) entered a $300 million senior secured first‑lien term loan with funds managed by Oaktree Capital. The facility has a five‑year maturity, two tranches (Tranche E $265M to refinance existing indebtedness; Tranche F $35M for growth), no amortization, and a fixed rate with potential step‑down tied to leverage.
The loan refinances prior debt, preserves a first‑priority lien on substantially all assets, and is intended to extend maturity and provide working capital to support operations and strategic growth.
Establishment Labs (NASDAQ: ESTA) will report first-quarter 2026 results before market open on May 6, 2026 and host a conference call at 8:30 am ET. Dial-in and a live/archived webcast are available via the company website. The release reiterates product portfolio, ongoing IRB‑approved pivotal studies, regulatory and manufacturing credentials, and global commercial footprint.
Establishment Labs (NASDAQ: ESTA) announced it has surpassed five million Motiva devices in market across more than 100 countries, reflecting adoption since 2010. The company reported over 25% revenue growth in 2025 and cited US market entry and its minimally invasive Preservé platform as drivers of 2026 momentum.
Preservé is priced about 30% higher than standard Motiva augmentation, and the company operates two ISO13485:2024 and FDA 21 CFR 820 compliant manufacturing facilities in Costa Rica.
Establishment Labs (NASDAQ: ESTA) announced a leadership transition effective March 9, 2026: Raj Denhoy moves from CFO to Senior Vice President, Global Strategy, and Cassandra “Sandra” Harris is appointed Senior Vice President and Chief Financial Officer.
Harris joins with prior CFO experience at Genesco and Tupperware and will lead finance while Denhoy focuses on strategic growth initiatives.
Establishment Labs (NASDAQ: ESTA) reported Q4 2025 revenue $64.6M (+45.2% YoY) and FY2025 revenue $211.1M (+27.2% YoY). Q4 adjusted EBITDA was a positive $5.5M and Q4 net loss from operations narrowed to $3.9M.
The company ended 2025 with $75.6M cash and provided 2026 revenue guidance of $264M–$266M (approximately +25%), with management projecting at least 25% growth in 2027.
Establishment Labs (NASDAQ: ESTA) will present at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 a.m. ET. CEO Peter Caldini and CFO Raj Denhoy will participate in a fireside chat.
A live webcast and archived replay will be available on the company's investor relations website.
Establishment Labs (NASDAQ: ESTA) will release fourth quarter 2025 financial results before market open on February 24, 2026 and host a conference call at 8:30 am ET that day.
The call accepts U.S./Canada dial-in (877) 407-8037, international +1 (201) 689-8037, conference ID 13758679, and will be live and archived on the company’s Investor Relations website. The company designs Motiva devices and minimally invasive platforms, holds 200+ patent applications, and manufactures in Costa Rica under ISO13485:2016 and FDA 21 CFR 820.
Establishment Labs (NASDAQ: ESTA) announced preliminary unaudited results for Q4 and fiscal 2025. Q4 2025 revenue is expected to be $64.0M–$65.0M, including $17.0M–$17.5M from Motiva sales in the United States. Full-year 2025 revenue is expected to be $210.5M–$211.5M, about 27% growth versus 2024, including $45.4M–$45.9M from U.S. Motiva sales. Year-end 2025 cash is expected to be approximately $75.5M, a $4.8M increase from Q3 2025. Results are preliminary, unaudited, and subject to change. Management reported positive adjusted EBITDA and said it expects to turn free cash flow positive later in 2026 while presenting full audited results on the February earnings call.
Establishment Labs (NASDAQ: ESTA) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 9:45 a.m. PT. CEO Peter Caldini and CFO Raj Denhoy will deliver the presentation.
A live webcast will be available on the company investor relations site and archived webcasts will be posted after the event. The company develops breast aesthetics and reconstruction technologies, with products in over 90 countries and over four million Motiva devices delivered since 2010. Key platforms include Mia Femtech, Preservé, GEM, Motiva Flora tissue expander, and the Zensor RFID/biosensor program; several products are in IRB‑approved pivotal studies. Manufacturing operates from two Costa Rica facilities under ISO13485:2016 and FDA 21 CFR 820 standards.